Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells

OBJECTIVES: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signallin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Mittal, Maroof, Asher, Gikas, Panos, Mittal, Gayatri, Keen, Richard, Baeten, Dominique, Shaw, Stevan, Roberts, Scott J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722278/
https://www.ncbi.nlm.nih.gov/pubmed/32723833
http://dx.doi.org/10.1136/rmdopen-2020-001306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722278/
https://www.ncbi.nlm.nih.gov/pubmed/32723833
http://dx.doi.org/10.1136/rmdopen-2020-001306

Ejemplares similares